If you would like to give your onychomycosis patients long-term treatment results, you may want to consider Lamisil, according to a recent study published in the March issue of Archives of Dermatology.
In reportedly the longest follow-up study of patients with toenail onychomycosis, researchers found that nearly half of the patients treated with Lamisil (terbinafine) remained mycologically cured five years after their initial treatment without any subsequent treatment.
“These findings offer patients and physicians evidence that toenail fungus can be effectively treated with 12 weeks of treatment with Lamisil,” notes Bardur Sigurgeirsson, MD, PhD, the lead author of the study and an Assistant Professor of Dermatology at the University of Iceland.
This actively controlled follow-up study tracked patients at six-month intervals for an average of 54 months. It included 74 Lamisil-treated patients (from three centers in Iceland) who participated in a previous study of onychomycosis patients. In the previous study (documented in the April 1999 issue of the British Medical Journal), 76 percent of Lamisil-treated patients achieved mycological cure at the end of an 18-month follow-up period.
Richard Pollak, DPM, uses Lamisil “extensively” and says his patients are “very satisfied” with it. While some of his patients have experienced recurrence after taking Lamisil, Dr. Pollak says the majority of his patients with onychomycosis see improvement three months after they start to take Lamisil. In 10 months to a year, they will see growth of the nail, according to Dr. Pollak.
Dr. Pollak feels Lamisil is safe and has few drug-to-drug interactions. He points out that he has only had to take one patient off the drug. A drawback to Lamisil is its cost, since many insurance companies do not cover oral agents, according to Dr. Pollak.